SlideShare a Scribd company logo
LOGO
Classification (-floxacins)
 First generation FQs
o Norfloxacin
o Ofloxacin
o Pefloxacin
o Ciprofloxacin
Note: Remember as NOP Cipro
 Second generation FQs
o Levofloxacin
o Lomefloxacin
o Moxifloxacin
o Gemifloxacin
o Sparfloxacin
Note: Remember as Levo Lome Moxi Gem Spark
Mechanism of Action
 The FQs enter the bacterium by passive
diffusion through porins in the outer
membrane
 Once inside the cell, they inhibit replication of
bacterial DNA by interfering with the action of
DNA gyrase (Topoisomerase II) and
Topoisomerase IV during bacterial growth and
reproduction
 Topoisomerases are the enzymes that change
the configuration of DNA by a ‘nicking — pass
through — resealing’ mechanism. They do not
change the DNAs primary sequence
Action of type II
DNA
Topoisomerase
Mechanism of Action
 Binding of quinolone to both the enzyme and
the DNA forms a ternary complex that inhibits
the resealing step, and can cause cell death by
inducing the cleavage of the DNA
 Because DNA gyrase is a bacteriospecific target
for anti-microbial therapy, cross resistance with
other, more commonly used anti-microbial
drugs is rare, but this is increasing in the case
of multi-drug resistant organisms
 The second site blocked by FQs– Topoisomerase
IV– is required by bacteria for cell division. It
has been implicated in the process of
In Gram-negative organisms (E.
coli), the inhibition of DNA gyrase
is more significant than that of
Topoisomerase IV, whereas in
Gram-positive organisms
(Streptococci), the opposite is
true.
Mechanism of Action: Flowchart
Uses
 Urinary tract infections:
 High cure rates, even in complicated cases or those with
indwelling catheters or prostatitis
 Chronic Pseudomonas infections respond less completely
 Gonorrhoea:
 Single dose of 500 mg was nearly 100% curative in PPNG as well
as non-PPNG infections, but the cure rates have declined due to
emergence of resistance and it is no longer a first line drug
 Chanchroid:
 500 mg BD for 3 days second line alternative drug to̶̶
Ceftriaxone/ Azithromycin
Uses
 Bacterial gastroenteritis:
 Use is reserved for severe cases of diarrhoea due to EPEC, Shigella, Salmonella,
Campylobacter jejuni infections
 Can reduce stool volume in cholera
 Typhoid:
 One of the 1st choice drugs in typhoid fever
 750 mg BD for 10 days is recommended or 200 mg i.v 12 hourly till oral therapy
can be instituted
 The advantages of Ciprofloxacin are:
o quick defervescence: fever usually subsides in 4-5 days
o Early abetment of symptoms, low incidence of complications and relapse
o Prevention of carrier state due to cidal action
 Ciprofloxacin can be used to treat typhoid carrier (750 mg BD for 4-8 weeks). This
has been found to achieve 92% eradication rate
Uses
 Bone, soft tissue, gynaecological and wound
infections:
 High cure rate have been obtained in osteomyelitis and joint
infections but prolonged treatment with high doses (6-8 weeks
with 750 md BD) is required
 Respiratory infections:
 Not a primary drug because Streptococci and Pneumococci have
low susceptibility
 However, RT infections due to Mycoplasma, Legionella,
H.influenzae respond
 Tuberculosis:
 One of the drugs in multidrug regimens used for resistant TB
 Also useful in atypical mycobacterial infections
Uses
 Gram negative septicaemias:
 Parenteral Ciprofloxacin may be combined with 3rd generation cephalosporin
or an aminoglycoside
 Prophylaxis:
 Prophylactic use for infections in neutropenic or cancer patients and other
susceptible patients
 Conjunctivitis:
 Topical therapy is effective
 Meningitis:
 Though penetration in CSF is not very good, it has been successfully used in
Gram negative bacterial meningitis especially that occuring in
immunocompromised patients or those with CSF shunts
Adverse effects
Fluoroquinolones have good safety record: side
effects occur in ~10% patients, but are
generally mild, withdrawal needed only in 1.5%
 GIT:
 Nausea, vomiting, anorexia, bad taste
 Does not affect gut anaerobes hence diarrhoea is infrequent̶
 CNS:
 Headache, dizziness, restlessness, anxiety, insomnia, impairment
of concentration and dexterity
 Tremor and seizures are rare: occur at high doses or when
predisposing factors are present
Adverse effects
 Skin/hypersensitivity:
 Rash, pruritus, photosensitivity, urticaria, swelling of lips etc.
 Serious cutaneous reactions are rare
 Tendinitis and tendon rupture:
 Risk of tendon damage is higher in patients above 60 yrs age and
in those receiving corticosteroids
 FQs should be stopped at the first sign of tendinitis
Contraindicated during pregnancy
Abbreviations used
 FQs- Fluoroquinolones
 DNA- Deoxyribose Nucleic Acid
 PPNG- Penicillinase Producing Neisseria Gonorrhoeae
 BD- Twice daily
 EPEC- Entero Pathogenic Escherichia Coli
 RT- Respiratory Tract
 TB- Tuberculosis
 CSF- Cerebro Spinal Fluid
 GIT- Gastro Intestinal Tract
 CNS- Central Nervous System
Kingsoft Office

More Related Content

What's hot

Cephalosporins- History,Classification,Sar,Synthesis,Mechanism of action,Uses...
Cephalosporins- History,Classification,Sar,Synthesis,Mechanism of action,Uses...Cephalosporins- History,Classification,Sar,Synthesis,Mechanism of action,Uses...
Cephalosporins- History,Classification,Sar,Synthesis,Mechanism of action,Uses...
Dr. Ravi Sankar
 
Antibiotics chloramphenicol and macrolides
Antibiotics   chloramphenicol and macrolidesAntibiotics   chloramphenicol and macrolides
Antibiotics chloramphenicol and macrolides
Grace Felciya
 
Broad spectrum antibiotics chloramphenicol
Broad spectrum antibiotics chloramphenicolBroad spectrum antibiotics chloramphenicol
Broad spectrum antibiotics chloramphenicol
SnehalChakorkar
 
Quinolones
QuinolonesQuinolones
Quinolones
Zulcaif Ahmad
 
Anthelmintics - drdhriti
Anthelmintics - drdhritiAnthelmintics - drdhriti
Anthelmintics - drdhriti
http://neigrihms.gov.in/
 
Cephalosporins - Pharmacology
Cephalosporins - Pharmacology Cephalosporins - Pharmacology
Cephalosporins - Pharmacology
Areej Abu Hanieh
 
Aminoglycosides
AminoglycosidesAminoglycosides
Aminoglycosides
Narasimha Kumar G V
 
Sulphonamide
SulphonamideSulphonamide
Sulphonamide
Mr.S.SEETARAM SWAMY
 
Aminoglycosides
AminoglycosidesAminoglycosides
Aminoglycosides
DrSahilKumar
 
Quinolones & Fluoroquinolones
Quinolones & FluoroquinolonesQuinolones & Fluoroquinolones
Quinolones & Fluoroquinolones
Dr Resu Neha Reddy
 
Penicillins, cephalosporins, amido penicillins
Penicillins, cephalosporins, amido penicillinsPenicillins, cephalosporins, amido penicillins
Penicillins, cephalosporins, amido penicillinsN K
 
Quinolones fluoroquinolones Pharmacology
Quinolones fluoroquinolones PharmacologyQuinolones fluoroquinolones Pharmacology
Quinolones fluoroquinolones Pharmacology
Koppala RVS Chaitanya
 
Fluoroquinolones
Fluoroquinolones Fluoroquinolones
Fluoroquinolones VIJAI KUMAR
 
Fluoroquinolones
FluoroquinolonesFluoroquinolones
Fluoroquinolones
Zainab&Sons
 
Betalactam antibiotics
Betalactam antibioticsBetalactam antibiotics
Betalactam antibiotics
Dr Pralhad Patki
 
Antimalarial drugs
Antimalarial drugs Antimalarial drugs
Antimalarial drugs
Naser Tadvi
 
Beta lactamase inhibitors
Beta lactamase inhibitorsBeta lactamase inhibitors
Beta lactamase inhibitors
JagirPatel3
 
Tetracyclines
TetracyclinesTetracyclines
Tetracyclines
kencha swathi
 

What's hot (20)

Cephalosporins- History,Classification,Sar,Synthesis,Mechanism of action,Uses...
Cephalosporins- History,Classification,Sar,Synthesis,Mechanism of action,Uses...Cephalosporins- History,Classification,Sar,Synthesis,Mechanism of action,Uses...
Cephalosporins- History,Classification,Sar,Synthesis,Mechanism of action,Uses...
 
Antibiotics chloramphenicol and macrolides
Antibiotics   chloramphenicol and macrolidesAntibiotics   chloramphenicol and macrolides
Antibiotics chloramphenicol and macrolides
 
Broad spectrum antibiotics chloramphenicol
Broad spectrum antibiotics chloramphenicolBroad spectrum antibiotics chloramphenicol
Broad spectrum antibiotics chloramphenicol
 
Quinolones
QuinolonesQuinolones
Quinolones
 
Anthelmintics - drdhriti
Anthelmintics - drdhritiAnthelmintics - drdhriti
Anthelmintics - drdhriti
 
Cephalosporins - Pharmacology
Cephalosporins - Pharmacology Cephalosporins - Pharmacology
Cephalosporins - Pharmacology
 
Aminoglycosides
AminoglycosidesAminoglycosides
Aminoglycosides
 
Sulphonamide
SulphonamideSulphonamide
Sulphonamide
 
Cephalosporins
CephalosporinsCephalosporins
Cephalosporins
 
Aminoglycosides
AminoglycosidesAminoglycosides
Aminoglycosides
 
Quinolones & Fluoroquinolones
Quinolones & FluoroquinolonesQuinolones & Fluoroquinolones
Quinolones & Fluoroquinolones
 
Penicillins, cephalosporins, amido penicillins
Penicillins, cephalosporins, amido penicillinsPenicillins, cephalosporins, amido penicillins
Penicillins, cephalosporins, amido penicillins
 
Quinolones fluoroquinolones Pharmacology
Quinolones fluoroquinolones PharmacologyQuinolones fluoroquinolones Pharmacology
Quinolones fluoroquinolones Pharmacology
 
2.sulfonamides
2.sulfonamides2.sulfonamides
2.sulfonamides
 
Fluoroquinolones
Fluoroquinolones Fluoroquinolones
Fluoroquinolones
 
Fluoroquinolones
FluoroquinolonesFluoroquinolones
Fluoroquinolones
 
Betalactam antibiotics
Betalactam antibioticsBetalactam antibiotics
Betalactam antibiotics
 
Antimalarial drugs
Antimalarial drugs Antimalarial drugs
Antimalarial drugs
 
Beta lactamase inhibitors
Beta lactamase inhibitorsBeta lactamase inhibitors
Beta lactamase inhibitors
 
Tetracyclines
TetracyclinesTetracyclines
Tetracyclines
 

Similar to Fluoroquinolones

Anti leprotic drugs
Anti leprotic drugsAnti leprotic drugs
Anti leprotic drugs
sanu108
 
Quinolones and Fluoroquinolone MOA,ADME,Spectrum of activity of Quinolones.
Quinolones and Fluoroquinolone MOA,ADME,Spectrum of activity of Quinolones.Quinolones and Fluoroquinolone MOA,ADME,Spectrum of activity of Quinolones.
Quinolones and Fluoroquinolone MOA,ADME,Spectrum of activity of Quinolones.
FahimAnwarRizwi
 
Quinolones
QuinolonesQuinolones
Quinolones
JagirPatel3
 
Fluoroquinolones
FluoroquinolonesFluoroquinolones
Fluoroquinolones
Zainab&Sons
 
Quinolones and fluroquinolones
Quinolones and fluroquinolonesQuinolones and fluroquinolones
Quinolones and fluroquinolones
zeelmevada
 
Presentation2 copy.pptx
Presentation2 copy.pptxPresentation2 copy.pptx
Presentation2 copy.pptx
ShadKawa
 
Chemotherapy
ChemotherapyChemotherapy
Chemotherapy
Dr Ramesh R
 
Quinolones
QuinolonesQuinolones
Quinolones
Shubham Marbade
 
FLUOROQUINOLONES.pptx
FLUOROQUINOLONES.pptxFLUOROQUINOLONES.pptx
FLUOROQUINOLONES.pptx
SumeetDumbre
 
Enteric fever
Enteric feverEnteric fever
Enteric fever
BadarJamal4
 
CHEMOTHERAPY OF TUBERCULOSIS AND LEPROSY.POWERPOINT.pptx
CHEMOTHERAPY OF TUBERCULOSIS AND LEPROSY.POWERPOINT.pptxCHEMOTHERAPY OF TUBERCULOSIS AND LEPROSY.POWERPOINT.pptx
CHEMOTHERAPY OF TUBERCULOSIS AND LEPROSY.POWERPOINT.pptx
SamuelAgboola11
 
Quinolones.pptx
Quinolones.pptxQuinolones.pptx
Quinolones.pptx
Subramani Parasuraman
 
ANTI TUBERCULAR DRUGS
ANTI TUBERCULAR DRUGS  ANTI TUBERCULAR DRUGS
ANTI TUBERCULAR DRUGS
paramesh Researcher
 
ANTI TUBERCULAR DRUGS
ANTI TUBERCULAR DRUGSANTI TUBERCULAR DRUGS
ANTI TUBERCULAR DRUGS
paramesh Researcher
 
Quinolones and Fluoroquinolones
Quinolones and FluoroquinolonesQuinolones and Fluoroquinolones
Quinolones and Fluoroquinolones
PrajwalGhatol1
 
Fluroquinolones 2
Fluroquinolones 2Fluroquinolones 2
Fluroquinolones 2VIJAI KUMAR
 
Antimycobacterial drugs.ppt
Antimycobacterial drugs.pptAntimycobacterial drugs.ppt
Antimycobacterial drugs.ppt
AbwoneKenneth
 
Leprosy
LeprosyLeprosy
Leprosy
punit patel
 
POWERPOINT PRESENTATION ON QUINOLINE
POWERPOINT PRESENTATION ON QUINOLINE  POWERPOINT PRESENTATION ON QUINOLINE
POWERPOINT PRESENTATION ON QUINOLINE
ayesharuqsar
 
Fluroquinolones 01 01-19
Fluroquinolones 01 01-19Fluroquinolones 01 01-19
Fluroquinolones 01 01-19
uma advani
 

Similar to Fluoroquinolones (20)

Anti leprotic drugs
Anti leprotic drugsAnti leprotic drugs
Anti leprotic drugs
 
Quinolones and Fluoroquinolone MOA,ADME,Spectrum of activity of Quinolones.
Quinolones and Fluoroquinolone MOA,ADME,Spectrum of activity of Quinolones.Quinolones and Fluoroquinolone MOA,ADME,Spectrum of activity of Quinolones.
Quinolones and Fluoroquinolone MOA,ADME,Spectrum of activity of Quinolones.
 
Quinolones
QuinolonesQuinolones
Quinolones
 
Fluoroquinolones
FluoroquinolonesFluoroquinolones
Fluoroquinolones
 
Quinolones and fluroquinolones
Quinolones and fluroquinolonesQuinolones and fluroquinolones
Quinolones and fluroquinolones
 
Presentation2 copy.pptx
Presentation2 copy.pptxPresentation2 copy.pptx
Presentation2 copy.pptx
 
Chemotherapy
ChemotherapyChemotherapy
Chemotherapy
 
Quinolones
QuinolonesQuinolones
Quinolones
 
FLUOROQUINOLONES.pptx
FLUOROQUINOLONES.pptxFLUOROQUINOLONES.pptx
FLUOROQUINOLONES.pptx
 
Enteric fever
Enteric feverEnteric fever
Enteric fever
 
CHEMOTHERAPY OF TUBERCULOSIS AND LEPROSY.POWERPOINT.pptx
CHEMOTHERAPY OF TUBERCULOSIS AND LEPROSY.POWERPOINT.pptxCHEMOTHERAPY OF TUBERCULOSIS AND LEPROSY.POWERPOINT.pptx
CHEMOTHERAPY OF TUBERCULOSIS AND LEPROSY.POWERPOINT.pptx
 
Quinolones.pptx
Quinolones.pptxQuinolones.pptx
Quinolones.pptx
 
ANTI TUBERCULAR DRUGS
ANTI TUBERCULAR DRUGS  ANTI TUBERCULAR DRUGS
ANTI TUBERCULAR DRUGS
 
ANTI TUBERCULAR DRUGS
ANTI TUBERCULAR DRUGSANTI TUBERCULAR DRUGS
ANTI TUBERCULAR DRUGS
 
Quinolones and Fluoroquinolones
Quinolones and FluoroquinolonesQuinolones and Fluoroquinolones
Quinolones and Fluoroquinolones
 
Fluroquinolones 2
Fluroquinolones 2Fluroquinolones 2
Fluroquinolones 2
 
Antimycobacterial drugs.ppt
Antimycobacterial drugs.pptAntimycobacterial drugs.ppt
Antimycobacterial drugs.ppt
 
Leprosy
LeprosyLeprosy
Leprosy
 
POWERPOINT PRESENTATION ON QUINOLINE
POWERPOINT PRESENTATION ON QUINOLINE  POWERPOINT PRESENTATION ON QUINOLINE
POWERPOINT PRESENTATION ON QUINOLINE
 
Fluroquinolones 01 01-19
Fluroquinolones 01 01-19Fluroquinolones 01 01-19
Fluroquinolones 01 01-19
 

Recently uploaded

Supporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptxSupporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptx
Jisc
 
CACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdfCACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdf
camakaiclarkmusic
 
Chapter 4 - Islamic Financial Institutions in Malaysia.pptx
Chapter 4 - Islamic Financial Institutions in Malaysia.pptxChapter 4 - Islamic Financial Institutions in Malaysia.pptx
Chapter 4 - Islamic Financial Institutions in Malaysia.pptx
Mohd Adib Abd Muin, Senior Lecturer at Universiti Utara Malaysia
 
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
EugeneSaldivar
 
Chapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptxChapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptx
Mohd Adib Abd Muin, Senior Lecturer at Universiti Utara Malaysia
 
Synthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptxSynthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptx
Pavel ( NSTU)
 
1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx
JosvitaDsouza2
 
South African Journal of Science: Writing with integrity workshop (2024)
South African Journal of Science: Writing with integrity workshop (2024)South African Journal of Science: Writing with integrity workshop (2024)
South African Journal of Science: Writing with integrity workshop (2024)
Academy of Science of South Africa
 
Thesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.pptThesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.ppt
EverAndrsGuerraGuerr
 
Best Digital Marketing Institute In NOIDA
Best Digital Marketing Institute In NOIDABest Digital Marketing Institute In NOIDA
Best Digital Marketing Institute In NOIDA
deeptiverma2406
 
Digital Artifact 2 - Investigating Pavilion Designs
Digital Artifact 2 - Investigating Pavilion DesignsDigital Artifact 2 - Investigating Pavilion Designs
Digital Artifact 2 - Investigating Pavilion Designs
chanes7
 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
DeeptiGupta154
 
Lapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdfLapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdf
Jean Carlos Nunes Paixão
 
Francesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptxFrancesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptx
EduSkills OECD
 
The Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptxThe Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptx
DhatriParmar
 
S1-Introduction-Biopesticides in ICM.pptx
S1-Introduction-Biopesticides in ICM.pptxS1-Introduction-Biopesticides in ICM.pptx
S1-Introduction-Biopesticides in ICM.pptx
tarandeep35
 
special B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdfspecial B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdf
Special education needs
 
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdfUnit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Thiyagu K
 
The Diamonds of 2023-2024 in the IGRA collection
The Diamonds of 2023-2024 in the IGRA collectionThe Diamonds of 2023-2024 in the IGRA collection
The Diamonds of 2023-2024 in the IGRA collection
Israel Genealogy Research Association
 
2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...
Sandy Millin
 

Recently uploaded (20)

Supporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptxSupporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptx
 
CACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdfCACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdf
 
Chapter 4 - Islamic Financial Institutions in Malaysia.pptx
Chapter 4 - Islamic Financial Institutions in Malaysia.pptxChapter 4 - Islamic Financial Institutions in Malaysia.pptx
Chapter 4 - Islamic Financial Institutions in Malaysia.pptx
 
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
 
Chapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptxChapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptx
 
Synthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptxSynthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptx
 
1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx
 
South African Journal of Science: Writing with integrity workshop (2024)
South African Journal of Science: Writing with integrity workshop (2024)South African Journal of Science: Writing with integrity workshop (2024)
South African Journal of Science: Writing with integrity workshop (2024)
 
Thesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.pptThesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.ppt
 
Best Digital Marketing Institute In NOIDA
Best Digital Marketing Institute In NOIDABest Digital Marketing Institute In NOIDA
Best Digital Marketing Institute In NOIDA
 
Digital Artifact 2 - Investigating Pavilion Designs
Digital Artifact 2 - Investigating Pavilion DesignsDigital Artifact 2 - Investigating Pavilion Designs
Digital Artifact 2 - Investigating Pavilion Designs
 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
 
Lapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdfLapbook sobre os Regimes Totalitários.pdf
Lapbook sobre os Regimes Totalitários.pdf
 
Francesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptxFrancesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptx
 
The Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptxThe Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptx
 
S1-Introduction-Biopesticides in ICM.pptx
S1-Introduction-Biopesticides in ICM.pptxS1-Introduction-Biopesticides in ICM.pptx
S1-Introduction-Biopesticides in ICM.pptx
 
special B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdfspecial B.ed 2nd year old paper_20240531.pdf
special B.ed 2nd year old paper_20240531.pdf
 
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdfUnit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdf
 
The Diamonds of 2023-2024 in the IGRA collection
The Diamonds of 2023-2024 in the IGRA collectionThe Diamonds of 2023-2024 in the IGRA collection
The Diamonds of 2023-2024 in the IGRA collection
 
2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...
 

Fluoroquinolones

  • 2. Classification (-floxacins)  First generation FQs o Norfloxacin o Ofloxacin o Pefloxacin o Ciprofloxacin Note: Remember as NOP Cipro  Second generation FQs o Levofloxacin o Lomefloxacin o Moxifloxacin o Gemifloxacin o Sparfloxacin Note: Remember as Levo Lome Moxi Gem Spark
  • 3. Mechanism of Action  The FQs enter the bacterium by passive diffusion through porins in the outer membrane  Once inside the cell, they inhibit replication of bacterial DNA by interfering with the action of DNA gyrase (Topoisomerase II) and Topoisomerase IV during bacterial growth and reproduction  Topoisomerases are the enzymes that change the configuration of DNA by a ‘nicking — pass through — resealing’ mechanism. They do not change the DNAs primary sequence
  • 4. Action of type II DNA Topoisomerase
  • 5. Mechanism of Action  Binding of quinolone to both the enzyme and the DNA forms a ternary complex that inhibits the resealing step, and can cause cell death by inducing the cleavage of the DNA  Because DNA gyrase is a bacteriospecific target for anti-microbial therapy, cross resistance with other, more commonly used anti-microbial drugs is rare, but this is increasing in the case of multi-drug resistant organisms  The second site blocked by FQs– Topoisomerase IV– is required by bacteria for cell division. It has been implicated in the process of
  • 6. In Gram-negative organisms (E. coli), the inhibition of DNA gyrase is more significant than that of Topoisomerase IV, whereas in Gram-positive organisms (Streptococci), the opposite is true.
  • 8. Uses  Urinary tract infections:  High cure rates, even in complicated cases or those with indwelling catheters or prostatitis  Chronic Pseudomonas infections respond less completely  Gonorrhoea:  Single dose of 500 mg was nearly 100% curative in PPNG as well as non-PPNG infections, but the cure rates have declined due to emergence of resistance and it is no longer a first line drug  Chanchroid:  500 mg BD for 3 days second line alternative drug to̶̶ Ceftriaxone/ Azithromycin
  • 9. Uses  Bacterial gastroenteritis:  Use is reserved for severe cases of diarrhoea due to EPEC, Shigella, Salmonella, Campylobacter jejuni infections  Can reduce stool volume in cholera  Typhoid:  One of the 1st choice drugs in typhoid fever  750 mg BD for 10 days is recommended or 200 mg i.v 12 hourly till oral therapy can be instituted  The advantages of Ciprofloxacin are: o quick defervescence: fever usually subsides in 4-5 days o Early abetment of symptoms, low incidence of complications and relapse o Prevention of carrier state due to cidal action  Ciprofloxacin can be used to treat typhoid carrier (750 mg BD for 4-8 weeks). This has been found to achieve 92% eradication rate
  • 10. Uses  Bone, soft tissue, gynaecological and wound infections:  High cure rate have been obtained in osteomyelitis and joint infections but prolonged treatment with high doses (6-8 weeks with 750 md BD) is required  Respiratory infections:  Not a primary drug because Streptococci and Pneumococci have low susceptibility  However, RT infections due to Mycoplasma, Legionella, H.influenzae respond  Tuberculosis:  One of the drugs in multidrug regimens used for resistant TB  Also useful in atypical mycobacterial infections
  • 11. Uses  Gram negative septicaemias:  Parenteral Ciprofloxacin may be combined with 3rd generation cephalosporin or an aminoglycoside  Prophylaxis:  Prophylactic use for infections in neutropenic or cancer patients and other susceptible patients  Conjunctivitis:  Topical therapy is effective  Meningitis:  Though penetration in CSF is not very good, it has been successfully used in Gram negative bacterial meningitis especially that occuring in immunocompromised patients or those with CSF shunts
  • 12. Adverse effects Fluoroquinolones have good safety record: side effects occur in ~10% patients, but are generally mild, withdrawal needed only in 1.5%  GIT:  Nausea, vomiting, anorexia, bad taste  Does not affect gut anaerobes hence diarrhoea is infrequent̶  CNS:  Headache, dizziness, restlessness, anxiety, insomnia, impairment of concentration and dexterity  Tremor and seizures are rare: occur at high doses or when predisposing factors are present
  • 13. Adverse effects  Skin/hypersensitivity:  Rash, pruritus, photosensitivity, urticaria, swelling of lips etc.  Serious cutaneous reactions are rare  Tendinitis and tendon rupture:  Risk of tendon damage is higher in patients above 60 yrs age and in those receiving corticosteroids  FQs should be stopped at the first sign of tendinitis Contraindicated during pregnancy
  • 14. Abbreviations used  FQs- Fluoroquinolones  DNA- Deoxyribose Nucleic Acid  PPNG- Penicillinase Producing Neisseria Gonorrhoeae  BD- Twice daily  EPEC- Entero Pathogenic Escherichia Coli  RT- Respiratory Tract  TB- Tuberculosis  CSF- Cerebro Spinal Fluid  GIT- Gastro Intestinal Tract  CNS- Central Nervous System